California Public Employees Retirement System Lowers Stock Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

California Public Employees Retirement System decreased its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 2.6% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 120,725 shares of the medical equipment provider’s stock after selling 3,228 shares during the quarter. California Public Employees Retirement System’s holdings in Lantheus were worth $7,485,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. FMR LLC lifted its stake in shares of Lantheus by 198.2% during the 3rd quarter. FMR LLC now owns 2,146,085 shares of the medical equipment provider’s stock valued at $149,110,000 after buying an additional 1,426,465 shares in the last quarter. Reinhart Partners LLC. increased its holdings in Lantheus by 50.4% in the 4th quarter. Reinhart Partners LLC. now owns 1,356,273 shares of the medical equipment provider’s stock valued at $84,089,000 after acquiring an additional 454,753 shares during the last quarter. American Century Companies Inc. increased its holdings in Lantheus by 41.9% in the 3rd quarter. American Century Companies Inc. now owns 1,300,904 shares of the medical equipment provider’s stock valued at $90,387,000 after acquiring an additional 384,093 shares during the last quarter. Westfield Capital Management Co. LP increased its holdings in Lantheus by 12.5% in the 3rd quarter. Westfield Capital Management Co. LP now owns 1,294,391 shares of the medical equipment provider’s stock valued at $89,934,000 after acquiring an additional 143,794 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in Lantheus by 1.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 832,367 shares of the medical equipment provider’s stock valued at $57,833,000 after acquiring an additional 15,004 shares during the last quarter. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on LNTH. Truist Financial lifted their price target on shares of Lantheus from $82.00 to $96.00 and gave the company a “buy” rating in a report on Friday. B. Riley lifted their price target on shares of Lantheus from $95.00 to $99.00 and gave the company a “buy” rating in a report on Thursday, April 18th. Mizuho lifted their price target on shares of Lantheus from $90.00 to $100.00 and gave the company a “buy” rating in a report on Friday. StockNews.com downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a report on Friday. Finally, JMP Securities restated a “market outperform” rating and issued a $100.00 target price on shares of Lantheus in a report on Friday, February 23rd. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $103.14.

Lantheus Stock Performance

Lantheus stock opened at $75.53 on Friday. The company’s 50-day moving average price is $62.67 and its 200-day moving average price is $62.83. Lantheus Holdings, Inc. has a twelve month low of $50.20 and a twelve month high of $100.85. The company has a quick ratio of 5.45, a current ratio of 5.80 and a debt-to-equity ratio of 0.69. The company has a market cap of $5.18 billion, a PE ratio of 16.28 and a beta of 0.52.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Thursday, February 22nd. The medical equipment provider reported $1.59 EPS for the quarter, topping analysts’ consensus estimates of $1.33 by $0.26. Lantheus had a net margin of 25.20% and a return on equity of 63.16%. The firm had revenue of $354.00 million during the quarter, compared to analysts’ expectations of $350.44 million. On average, equities research analysts forecast that Lantheus Holdings, Inc. will post 5.96 EPS for the current fiscal year.

Insider Buying and Selling

In other news, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of the company’s stock in a transaction that occurred on Wednesday, March 6th. The stock was purchased at an average cost of $0.95 per share, with a total value of $57,409,487.05. Following the purchase, the insider now owns 116,773,394 shares in the company, valued at $110,934,724.30. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Lantheus news, Director Mary Anne Heino sold 93,863 shares of the business’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $65.31, for a total value of $6,130,192.53. Following the completion of the sale, the director now directly owns 251,643 shares of the company’s stock, valued at approximately $16,434,804.33. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, major shareholder Lantheus Alpha Therapy, Llc acquired 60,431,039 shares of the stock in a transaction on Wednesday, March 6th. The stock was bought at an average cost of $0.95 per share, with a total value of $57,409,487.05. Following the completion of the transaction, the insider now owns 116,773,394 shares in the company, valued at $110,934,724.30. The disclosure for this purchase can be found here. In the last ninety days, insiders sold 94,545 shares of company stock valued at $6,169,936. Company insiders own 1.50% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.